DAIC

FEBRUARY 23, 2024

The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease," said James P. "The Presented at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting Boston MA 2023.

Ischemia 105

Ischemia Coronary Artery Disease Physiology Cardiovascular Imaging 105

DAIC

JANUARY 23, 2024

a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024. milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. ,

Reimbursement 105

Reimbursement Coronary Artery Disease CMS Technology 105

Dr. Paddy Barrett

APRIL 5, 2024

A common feedback I get is that people with existing coronary artery disease feel like it doesn’t apply to them. Arguably, applying the principles of prevention offers more bang for buck in the short term for people WITH coronary artery disease than those without coronary artery disease.

Heart Disease 97

Heart Disease Coronary Artery Disease Heart Attack Heart attacks 97

DAIC

MAY 8, 2024

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 10390, May 2023, pp.

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Myocardial Infarction Ischemia 111

Circulation: Genomic and Precision Medicine

JULY 6, 2023

Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 480-482, October 1, 2023.

Coronary Artery Disease 40

Coronary Artery Disease Cholesterol Atherosclerosis Circulation 40

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.

Coronary Artery Disease 105

Coronary Artery Disease Stents Stent Technology 105

DAIC

DECEMBER 19, 2023

milla1cf Tue, 12/19/2023 - 17:05 December 19, 2023 — Siemens Healthineers announced the Food and Drug Administration ( FDA ) clearance of the Somatom Pro.Pulse, a dual-source computed tomography scanner designed to be more affordable for a wide range of healthcare facilities, including outpatient diagnostic centers.

Chest Pain 104

Chest Pain Coronary Artery Disease Technology Outpatient 104

DAIC

MARCH 20, 2024

Our efforts to expand therapeutic possibilities, underlined by the introduction of the Freesolve RMS for coronary artery disease treatment, will continue in the BTK indication with this groundbreaking innovation.” Eurointervention; 2023;18-online publish-ahead-of-print January 2023. 4 Seguchi M.,

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Coronary Artery Disease Technology 105

Heart 2023 Conference

JANUARY 17, 2024

The institute specializes in the treatment of coronary artery diseases, arrhythmia, advanced heart failure and heart transplantation, structural heart disease, cardiogenetics, and congenital heart disease. Additionally, it offers comprehensive cardiac screening and preventive care.

Congenital Heart Disease 49

Congenital Heart Disease Coronary Artery Disease Heart Transplant Transplant 49

DAIC

JUNE 27, 2024

Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heart disease, debates and games and early career topics. for all attendees.

Congenital Heart Disease 105

Congenital Heart Disease Coronary Artery Disease Congenital Heart Disease 105

Frontiers in Cardiovascular Medicine

FEBRUARY 12, 2024

Background There is mounting data supporting the use of drug-coated balloons (DCB) not only for treatment of in-stent restenosis (ISR), but also in native coronary artery disease. The mean age was 68 ± 10 years, 48 (38%) patients had an acute coronary syndrome. Angiograms and outcomes were independently adjudicated.

Coronary Artery Disease 59

Coronary Artery Disease Myocardial Infarction Stents Stent 59

Journal of Cardiovascular Pharmacology

JANUARY 8, 2024

Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease in modern clinical practice, alone or in combination with conventional treatment. From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease Angina Heart Failure 40

DAIC

FEBRUARY 13, 2024

It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease. “We Presented at the American College of Cardiology Annual Scientific Meeting New Orleans LA 2023. 2023 Dec 12:jead339. Barcelona, Spain.

Coronary Artery Disease 103

Coronary Artery Disease Ischemia Atherosclerosis Cardiovascular Imaging 103

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Stroke Journal

NOVEMBER 9, 2023

Stroke, Volume 54, Issue 12 , Page 3182-3189, December 1, 2023. The identification of a variant in theHDAC9gene as a risk factor for large-artery atherosclerotic stroke, and subsequently coronary artery disease, has opened novel treatment pathways for stroke and more widely atherosclerotic disease.

Stroke 40

Stroke Strokes Atherosclerosis Coronary Artery Disease 40

DAIC

JANUARY 15, 2024

This builds on the history of Echo diagnostic algorithms developed by Ultromics including the first ever AI diagnostic, EchoGo® Pro for the detection of coronary artery disease, which was FDA cleared in 2021 and is undergoing a prospective clinical trial in the UK.

Ultrasound 119

Ultrasound Coronary Artery Disease Innovation Heart Failure 119

Dr. Paddy Barrett

OCTOBER 31, 2023

An elevated Lp(a) is a common genetic factor that is independently and causally related to premature coronary artery disease. The occurrence of disease in this instance is probabilistic, not deterministic. An elevated Lp(a) does increase the risk of early cardiovascular disease, but that risk is not set in stone.

Coronary Artery Disease 52

Coronary Artery Disease Heart Disease Atherosclerosis Cardiovascular Disease 52

Dr. Paddy Barrett

JANUARY 30, 2024

The key issue when it comes to the near-term risk of a heart attack is whether you already have coronary artery disease and how much of it. It’s not a good test for assessing for plaque in the arteries. 2023, 2 Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med.

Heart Disease 69

Heart Disease Heart Attack Heart attacks Plaque 69

The British Journal of Cardiology

NOVEMBER 29, 2023

The most prevalent diagnosis post-CMR in our cohort was ischaemic heart disease, including ischaemic cardiomyopathy and coronary artery disease. The most common indication for inpatient CMR was to investigate for cardiomyopathy (53% of patients).

Inpatient 52

Inpatient Coronary Artery Disease Outpatient Cardiomyopathy 52

Journal of Cardiovascular Pharmacology

NOVEMBER 6, 2023

Abstract: Colchicine reduces atherothrombotic cardiovascular events in coronary artery disease (CAD) due to its anti-inflammatory effect. Colchicine reduces atherothrombotic cardiovascular events in coronary artery disease (CAD) due to its anti-inflammatory effect. All rights reserved.

Coronary Artery Disease 40

Coronary Artery Disease Outcomes 40

Dr. Paddy Barrett

FEBRUARY 27, 2024

mmol/l (130 mg/dl) or below, between 20-50% will already have coronary artery disease. As HBA1c increases, even in the normal range, the probability of coronary artery disease increases. 2023 Nov, 82 (22) 2152–2162. For HBA1c, the trend is similar. JAMA Cardiol. 2020;5(9):1011–1018.

Risk Factors 102

Risk Factors Heart Disease Heart Attack Heart attacks 102

BoardVitals - Cardiovascular

MAY 15, 2022

The Cardiology MOC exam will be offered on April 3, 2023, and October 11, 2023. The Cardiology MOC exam covers the following subjects : Arrhythmias 15% Coronary Artery Disease 21.5% What are some things you need to know before you sit for the exam? How much does the exam cost? What does the exam cover?

Certification 52

Certification Congenital Heart Disease Coronary Artery Disease Cardiovascular Disease 52

Circulation

NOVEMBER 8, 2023

Circulation, Volume 148, Issue 24 , Page 1958-1973, December 12, 2023. BACKGROUND:Reducing cardiovascular disease burden among women remains challenging.

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction Circulation Plaque 40

Clinical Trial Results

NOVEMBER 13, 2023

Disclosures: TBD

Coronary Artery Disease 40

Coronary Artery Disease Risk Factors Technology 40

DAIC

JANUARY 25, 2024

mg tablets), together with Caristo Diagnostics , a leading cardiac disease diagnostics company with the novel CaRi-Heart technology to visualize and quantify coronary inflammation, announced today their collaboration to improve awareness and clinical education about the central role of inflammation in coronary artery disease.

Heart Attack 110

Heart Attack Heart attacks Technology Cardiovascular Disease 110

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionTransient Ischemic Attack (TIA) is a common neurologic condition characterized by temporary, focal cerebral ischemia that results in reversible neurological deficits without tissue infarction.

Diabetes 40

Diabetes Coronary Artery Disease Atrial Fibrillation Dementia 40

Cardiology Update

FEBRUARY 14, 2024

In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stent thrombosis, and repeat revascularization. Am Heart J.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Disease Thrombosis Research 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. This study presented two patients with symptomatic common carotid artery occlusion (CCAO) who subsequently underwent subclavian‐carotid artery bypass surgery using the polytetrafluorethylene graft.

Outcomes 40

Outcomes Coronary Artery Disease Chest Pain Aortic 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionThere is a higher prevalence of diabetes mellitus type 2 in Hispanics as compared to other ethnic groups in the United States. or greater.

Outcomes 40

Outcomes Angioplasty Atrial Fibrillation Diabetes 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionSubarachnoid Hemorrhage (SAH) is the leading cause of morbidity and mortality in stroke patients, associated with severe neurological, infectious, and thromboembolic complications. x) from 2016‐2019.

Hemorrhage 40

Hemorrhage Coronary Artery Disease Obesity Heart Failure 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionLimb‐shaking transient ischemic attack (LS‐TIA) is a rare disorder characterized by brief, irregular, involuntary movements of the extremities with or without loss of consciousness.

Coronary Artery Disease 40

Coronary Artery Disease Blood Pressure Atherosclerosis Stroke 40

DAIC

JANUARY 8, 2024

Our anticipated acquisition of MIM Software will mark a key moment in the evolution of our technology.

Innovation 105

Innovation Technology Patient Care Cancer 105

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. & vs 5.60%), PVD (6.17% and 6.27% vs 4.88%), coronary artery disease (20.52% and 20.52% vs 17.83%), chronic renal failure (20.52% and 22.21% vs 17.83%), and heart failure (15.98% and 15.87% vs 12.47%) (p<0.001 for all).

Hemorrhage 40

Hemorrhage Risk Factors Coronary Artery Disease Obesity 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionMycotic aneurysms of paraspinal arteries are a rare finding. Furthermore, knowledge regarding the management of paraspinal mycotic aneurysms and the efficacy of endovascular repair of these lesions is scarce.⁴MethodsWe

Aneurysm 40

Aneurysm Peripheral Arterial Disease Coronary Artery Disease ICU 40

Dr. Anish Koka

MAY 16, 2023

Diamond and Forrester accomplished this by first establishing the prevalence of coronary artery disease based on how clinically likely patients with chest pain symptoms were found to have coronary disease based on a coronary angiogram. Thanks for reading Dr. Anish Koka's Newsletter! This happens.

Chest Pain 52

Chest Pain Coronary Artery Disease Cancer Heart Attack 52

DAIC

JANUARY 3, 2024

6 Also in 2023, HeartFlow released its RoadMap Analysis which helps identify and quantify narrowings in the coronary arteries and has demonstrated a 25% faster CCTA read time. REVEALPLAQUE Study, SCCT 2023. HeartFlow is committed to serving customers quickly and reliably with a median turnaround time less than 1.5

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59

Coronary Artery Disease Journal

MARCH 7, 2024

Databases were searched for relevant articles published before 10 November 2023. Methods This meta-analysis was performed based on PRISMA guidelines after registering in PROSPERO (CRD42023472652). Pertinent data from the included studies were extracted and analyzed using RevMan v5.4.

Myocardial Infarction 40

Myocardial Infarction Ischemia Thrombosis Stents 40